PaxMedica is a biopharmaceutical company focused on developing innovative treatments for unmet needs in neurodevelopmental disorders.
PaxMedica has raised $7.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in November 2023.
PaxMedica's investors include The Lind Partners, Lincoln Park Capital Fund.
PaxMedica is headquartered in Tarrytown, United States.
PaxMedica is a biopharmaceutical company focused on developing innovative treatments for unmet needs in neurodevelopmental disorders.
PaxMedica is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"PaxMedica — Funding & Investors." VCBacked, November 20, 2023, https://www.vcbacked.co/company/paxmedica. Accessed August 14, 2026.
VCBacked. (2023). PaxMedica — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/paxmedica
{{cite web |title=PaxMedica — Funding & Investors |url=https://www.vcbacked.co/company/paxmedica |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated